About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 3NCT00499590

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD

The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizu...

Lead sponsor: OPKO Health, Inc.•55 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

OPKO Health, Inc.

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients must be age 50 years or older
•2. Patients must have predominantly classic, minimally classic or occult with no classic lesions secondary to Age Related Macular Degeneration.
•3. The study eye must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen equivalent).
•4. Patients must be willing and able to return for scheduled monthly follow-up visits for two-years.

Exclusion Criteria

•1. Prior pharmacologic treatment for AMD in the study (patients can not have previously received Avastin®/Lucentis®, Macugen®, or any other anti-VEGF agents, steroid treatments, PDT, radiation treatment, or any experimental therapies for AMD in the study eye)
•2. Any intraocular surgery of the study eye within 12 weeks of screening
•3. Previous posterior vitrectomy of the study eye
•4. Advanced glaucoma or intraocular pressure above 22 mm Hg in the study eye despite treatment.

Related studies

RECRUITINGPhase 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269 · Geographic Atrophy Secondary to Age-related Macular Degeneration

RECRUITINGPhase 1

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05803785 · Age-Related Macular Degeneration

High Resolution Retinal Imaging

NCT01866371 · Stargardts, Retinitis Pigmentosa, and more

RECRUITINGPhase 1/2

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration

Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab

NCT07550777 · Diabete Mellitus, Retina Vein Occlusion, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 6, 2014Terms

Trial snapshot

StatusTERMINATED

PhasePHASE3

Enrollment338

Start dateAug 2007

Last updatedOct 6, 2014

Condition

Macular Degeneration

Locations shown

Retinal Consultants of Arizona (site 209)

Phoenix, Arizona

Associated Retina Consultants (site 286)

Phoenix, Arizona

Retina Centers PC (site 215)

Tucson, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2014Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions